PRLD Prelude Therapeutics Inc Insider Trading

Director Bonita David P bought 2,815,315 shares for $12,499,998.60 at $4.44 on 2026-04-21

Director Bonita David P made 2 separate purchases totaling 2,815,315 shares for $12,499,998.60 at a blended average price of $4.44, representing a substantial open-market acquisition. The transaction brought post-transaction holdings to 1,126,126 shares. The stock trades at $4.40 currently, 30-day change +41.0% and 90-day change +117.8%, indicating strong recent momentum. However, the director's cross-ticker track record shows 1 prior buy with an average 90-day return of -75.3% and a 0.00% win rate, raising a material question about the predictive value of insider buying at this filer. The company remains unprofitable (net income of $-19,725,000.00 for the latest fiscal period) despite quarterly revenue of $6,500,000.00 and annual revenue growth of +73.4%, suggesting execution risk persists despite sales momentum.

ORBIMED ADVISORS LLC (Director) purchased 2,815,315 shares for $12,499,998.60 at $4.44 on 2026-04-21

ORBIMED ADVISORS LLC, a Director, executed 2 separate purchases totaling 2,815,315 shares (2.82M shares) for $12,499,998.60 ($12.5M) at a blended average price of $4.44 on 2026-04-21. The transaction represents a substantial commitment: post-transaction holdings of 1,126,126 shares reflect a net increase from a pre-transaction position of -1,689,189 shares. The stock is currently trading at $4.40, only -20.3% from its 52-week high of $5.52 and up +41.0% over 30 days and +117.8% over 90 days. ORBIMED's cross-ticker track record shows strong performance on buys (5 prior buys with 100% 90-day win rate and +469.9% average 30-day return) against a more mixed record on sells (75% well-timed rate). Prelude Therapeutics remains unprofitable with quarterly revenue of $6,500,000 ($6.5M) and net income of $-19,725,000 ($-19.7M), though the company posted +73.4% annual revenue growth. The large capital commitment by a director at current valuations into an unprofitable but high-growth biotech company should be monitored against the company's path to profitability and execution on its pipeline.

CCO Combs buys 100,000 PRLD shares at $0.69; stock down 89.3% from 52-week high, insider's prior buys show 0% 90-day win rate

Andrew Combs, Chief Chemistry Officer, purchased 100,000 shares of Prelude Therapeutics at $0.69 on 2025-03-25, increasing his holdings to 480,123 shares (+26.3% vs pre-transaction). The purchase occurs in a severely distressed context: the stock is trading at $0.68 (current price), down 89.3% from its 52-week high of $6.37, and has declined 49.2% over the past 90 days. Combs' cross-ticker track record across all his open-market purchases shows an 0% win rate at the 90-day mark, with prior trades at PRLD similarly unsuccessful—his two prior buys at this ticker on 2024-12-20 and 2024-12-23 each resulted in 90-day losses of 36.0% and 48.0% respectively. The company remains fundamentally distressed: net income was $-32.3M (latest quarter) against revenue of $3.0M, and market capitalization stands at $37.5M, leaving minimal margin for error.

CEO Vaddi Krishna bought 675,000 shares of PRLD at $0.69 on 2025-03-25, raising stake 51.0% to 2.00M shares as stock trades -89.3% from 52-week high.

Vaddi Krishna, CEO of Prelude Therapeutics, executed a substantial open-market purchase of 675,000 shares at $0.69 on 2025-03-25, increasing his holdings by 51.0% from 1.32M to 2.00M shares. This transaction occurred in the context of severe equity deterioration: the stock is trading at $0.68 (current price), down 89.3% from its 52-week high of $6.37, and has declined 49.2% over the prior 90 days. The company's fundamentals show persistent unprofitability, with net income of $-32.3M against quarterly revenue of $3.0M and a market cap of $37.5M. Notably, this purchase is part of a rapid accumulation pattern—the CEO executed five separate buys at PRLD in the prior 12 days (2025-03-13 through 2025-03-21), with outcomes on those earlier trades not yet measurable at the 90-day horizon. His cross-ticker buy track record shows 10 prior open-market purchases with an average 90-day return of -20.5% and a 0.00% win rate, indicating a pattern of poorly-timed entries that preceded further declines. The current transaction signals either conviction in a depressed valuation or continued accumulation at progressively lower prices despite mounting losses.

CEO Vaddi Krishna buys 20,416 shares at $0.73 across 2 transactions as stock trades -88.7% from 52-week high

Vaddi Krishna, CEO of Prelude Therapeutics, executed 2 separate purchases totaling 20,416 shares for $14,909.43 on 2025-03-20 and 2025-03-21 at $0.73 per share, increasing his holdings by 1.6% to 1.32M shares. The timing merits scrutiny: the stock currently trades at $0.72, having declined 88.7% from its 52-week high of $6.37 and down 17.3% in the prior 30 days. Across his prior 5 trades at PRLD (all buys on 2025-03-12 through 2025-03-17), none of the completed outcomes demonstrate value creation—his cross-ticker track record shows 0 wins at the 90-day mark. Against this backdrop, the company remains deeply unprofitable: latest quarterly revenue of $3.0M against a net loss of $32.3M, with a market cap of only $39.7M. Multiple near-simultaneous buys during a severe drawdown, combined with persistent losses and zero past success at capturing rebounds, suggests either conviction in a turnaround or mechanical accumulation in the face of collapsing valuation.

CEO Vaddi Krishna bought 39,105 shares at $0.75 over 2 transactions, now holding 1.30M shares; stock down -88.8% from 52-week high.

Vaddi Krishna purchased 39,105 shares across 2 separate transactions for a blended average price of $0.75, increasing his holdings from 1.26M to 1.30M shares (+3.1%). The purchases occurred on 2025-03-14 and 2025-03-17, following a prior buy by the same executive on 2025-03-13 and 2025-03-12. The stock is currently trading at $0.71, down 26.8% over the past 30 days and -88.8% from its 52-week high of $6.37, indicating severe deterioration in valuation since the broader peak. Fundamentals show the company is unprofitable with a net income of $-32.3M against quarterly revenue of $3.0M and a market cap of $39.2M. Across his prior 5 documented trades at this ticker, Krishna's timing has been mixed; his 90-day win rate is 0.00%, with none of his prior PRLD purchases showing measurable positive 90-day outcomes, suggesting this purchase pattern may not reflect successful timing decisions.

CEO Vaddi Krishna buys 97,500 shares at $0.71–$0.72 on 2025-03-12/13 as stock trades 88.4% below 52-week high.

CEO Vaddi Krishna executed two separate purchases totaling 97,500 shares for $69,564.00 at a blended average price of $0.71, increasing his holdings by 8.4% to 1,264,775 shares. The timing merits scrutiny: PRLD is trading at $0.74, down 88.4% from its 52-week high of $6.37 and down 18.3% over the past 30 days, while the company posted a $-32,271,000.00 net loss in its latest full fiscal year against revenue of only $3,000,000.00. Krishna's prior five trades at PRLD have generated mixed near-term results (12.6%, 18.3%, -4.6%, -1.6%), and his cross-ticker track record shows an average 30-day return of 6.2% on five prior buys, yet none of his same-ticker purchases have yet achieved measurable 90-day outcomes to confirm whether he has been early or late into recoveries. The stock's steep valuation decline and persistent unprofitability create a backdrop where a large insider purchase could indicate either conviction in a turnaround or simply accumulation at depressed prices without directional visibility.

PRLD CEO buys 5,000 shares at $1.21 on 2024-12-31; stock -78.2% from 52-week high

Vaddi Krishna purchased 5,000 shares at $1.21 on 2024-12-31, increasing his holdings from 137,553 to 142,553 shares. The stock is trading at $1.39 currently, down 78.2% from its 52-week high of $6.37, and Prelude Therapeutics remains deeply unprofitable with a net income of $-32,271,000.00 on quarterly revenue of $3,000,000.00. Krishna has completed three consecutive open-market purchases at PRLD in three days (2024-12-18, 2024-12-19, and 2024-12-31), but the brief timeframe means outcomes are not yet measurable and his cross-ticker track record shows only 3 prior buys overall. The transaction is disclosed without flags indicating discretionary timing, but occurs in a context of severe valuation pressure and material operating losses with no evident signal regarding near-term business inflection.

CEO Vaddi Krishna bought 10,000 shares at $1.20 on 2024-12-30; cluster pattern with 2 other insiders buying within 14 days.

Vaddi Krishna, as CEO, purchased 10,000 shares of PRLD at $1.20 on 2024-12-30, bringing his holdings to 137,553 shares and representing a +7.8% increase. The transaction occurred while the stock traded -80.4% from its 52-week high of $6.37, creating a backdrop of significant price depreciation. A cluster pattern emerged with 2 other insiders also buying within the past 14 days. The company's fundamentals remain challenged: it generated $3,000,000 in the latest quarter but reported a net loss of $-32,271,000 and maintains an unprofitable annual profile. This concurrent buying activity by multiple insiders during a sharp downturn warrants monitoring to understand whether it reflects internal confidence in turnaround potential or other strategic positioning.

Chief Chemistry Officer Combs buys 63,075 shares across 2 transactions ($1.15–$1.37); cluster buy pattern with 2 other insiders in 14 days

Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics, executed 2 separate purchases totaling 63,075 shares for $85,538.25 over three trading days, increasing his holdings by 20.1% to 377,623 shares. The purchases at $1.15 and $1.37 occur while the stock trades 78.0% below its 52-week high of $6.37, and come as part of a broader insider buying cluster—2 other executives also acquired shares within the same 14-day window. Against the backdrop of unprofitability (latest quarter net income: $-32,271,000.00) and minimal recent revenue ($3,000,000.00), the coordinated accumulation by multiple insiders during a period of elevated price pressure warrants scrutiny of insider conviction and forward guidance.